【Introduction】
Product Name: Human PD-L1 Antibody (Durvalumab, Research Use)
Catalog Number: NBR-0073
Target Name: PD-L1
Trade Name: Durvalumab
Antibody Drug Description: Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[6] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).
【Description】
Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS:N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG
【Gene Information】
Gene Name: PD-L1
Synonyms: CD274; B7H1; PDL1
Target Description: Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response.
Ensembl: ENSG00000120217
Uniprot: Q9NZQ7